A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia

A 77-year-old-man with renal cell carcinoma who was undergoing nivolumab treatment visited our department due to hyperglycemia; his plasma glucose level was 379 mg/dL. Although his serum C-peptide immunoreactivity (CPR) level was preserved (5.92 ng/mL), we suspected an onset of fulminant type 1 diab...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Naoko, Tsurutani, Yuya, Katsuragawa, Sho, Kubo, Haremaru, Sunouchi, Takashi, Hirose, Rei, Hoshino, Yoshitomo, Ichikawa, Masahiro, Takiguchi, Tomoko, Yukawa, Hiroko, Arioka, Hitoshi, Saitou, Jun, Nishikawa, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815891/
https://www.ncbi.nlm.nih.gov/pubmed/31243198
http://dx.doi.org/10.2169/internalmedicine.2780-19
Descripción
Sumario:A 77-year-old-man with renal cell carcinoma who was undergoing nivolumab treatment visited our department due to hyperglycemia; his plasma glucose level was 379 mg/dL. Although his serum C-peptide immunoreactivity (CPR) level was preserved (5.92 ng/mL), we suspected an onset of fulminant type 1 diabetes mellitus (FT1DM) and immediately started insulin therapy. His CPR levels gradually decreased and were depleted within 1 week. We later discovered that the patient's casual CPR level had been abnormally high (11.78 ng/mL) 2 weeks before his admission. Hence, the possibility of FT1DM in hyperglycemic patients undergoing nivolumab treatment should not be excluded, even with a preserved CPR level.

Ejemplares similares